Electra Begins Testing North American Feedstock for Cobalt Refinery

(TSX-V:ELBM),(NASDAQ:ELBM), TORONTO, July 31, 2025 (GLOBE NEWSWIRE) — Electra Battery Materials Corporation (NASDAQ: ELBM; TSX-V: ELBM) (“Electra” or the “Company”) announces the start of metallurgical testing on cobalt feedstock from two strategic North American sources: the historic Cobalt Camp in Ontario and home to Electra's refinery, and the Company's Iron Creek cobalt and copper project […]

SNDL Reports Second Quarter 2025 Financial and Operational Results

The Company Delivers Positive Operating Income SNDL Inc. (NASDAQ: SNDL) (CSE: SNDL) (“SNDL” or the “Company”) reported its financial and operational results for the secondquarter ended June 30, 2025. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated. https://mma.prnewswire.com/media/2741582/SNDL_Inc__SNDL_Reports_Second_Quarter_2025_Financial_and_Operati.jpg SNDL has also posted a supplemental investor presentation

Arcadia Announces Commitments to Support the CMS-Aligned Network Strategy

BOSTON, July 31, 2025 (GLOBE NEWSWIRE) — Arcadia(R) (arcadia.io), a leading healthcare data platform, today announced deeper industry collaboration to provide customers with a streamlined pathway into the Centers for Medicare & Medicaid Services' (CMS) Aligned Network Strategy. These efforts will enable Arcadia's customers–including Accountable Care Organizations (ACOs), health systems, and health plans–to connect to

Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

(NASDAQ:KTTA),(NASDAQ:KTTAW), MIAMI, July 31, 2025 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the treatment of neurofibromatosis type 1 (NF1) and other MAPK pathway driven indications, today announced the Company has completed enrollment and initial dosing of three subjects

BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December

(NASDAQ:BCRX), RESEARCH TRIANGLE PARK, N.C., July 31, 2025 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its president and chief executive officer, Jon Stonehouse, has informed the board of directors of his intention to retire on December 31, 2025. The board has appointed Charlie Gayer, currently the company's chief commercial officer (CCO),

Allegro MicroSystems Reports First Quarter 2026 Results

(NASDAQ:ALGM), MANCHESTER, N.H., July 31, 2025 (GLOBE NEWSWIRE) — Allegro MicroSystems, Inc. (“Allegro” or the “Company”) (Nasdaq: ALGM), a global leader in power and sensing semiconductor solutions for motion control and energy efficient systems, today announced financial results for its first quarter ended June 27, 2025. “We delivered strong first quarter results, with sales of

Enlil Announces Seven Strategic Partnerships to Accelerate MedTech Innovation and Customer FDA Clearance Success

Enlil, Inc., a Shifamed Portfolio Company and leader in enabling MedTech product innovation, today announced seven new strategic partnerships formed to date in 2025. These agreements, spanning referral, reseller, deployment, and regulatory consulting collaborations, strengthen Enlil's position as a transformative platform in the medical device development ecosystem. https://mma.prnewswire.com/media/2633137/Enlil_Logo.jpg Our shared mission is to simplify the

SAFE Raises $70 Million Series C to Build CyberAGI; Unveils World’s First Fully Autonomous CTEM Solution

Led by Avataar Ventures, funding accelerates SAFE's pursuit of cybersecurity superintelligence – while doubling down on its Agentic AI-first approach with the Continuous Threat Exposure Management (CTEM) launch – building on its category-defining leadership in the CRQ and TPRM markets SAFE, the category leader in Cyber Risk Quantification (CRQ) and the first company to deliver

Marengo Therapeutics Bolsters Advisory Strength with Appointment of Dr. Mikael Dolsten to its Board of Directors and Dr. Josep Tabernero to its Scientific Advisory Board

— Former Chief Scientific Officer & President of R&D at Pfizer, Dr. Mikael Dolsten brings decades of R&D and strategic leadership experience in pharmaceutical medicine to guide Marengo's next phase of growth and value creation — World-renowned oncology expert and Director of the Vall d'Hebron Institute of Oncology (VHIO), Dr. Josep Tabernero joins SAB to

CytoSorbents Leads a New Era in Sepsis Treatment

CytoSorbents highlights the vital and evolving role of CytoSorb® in the treatment of sepsis and septic shock ahead of its World Sepsis Day Global Webinar on September 10th CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, highlights new studies that

Scroll to Top